Wednesday, 20 February 2013
Hammersmith Medicines Research (www.hmrlondon.com) and researchers at University College London are working in partnership on a study to investigate the safety of a new medication treatment in people with Down's syndrome. It is the first study of the new treatment in people with Down's syndrome. The project is funded by the drug company Roche.
They hope the new treatment will improve learning, memory and language skills. Impairment of mental function in people with Down's syndrome is thought to be caused partly by overactivity of the GABA α5 receptor subunit at the junctions between nerves inthe brain. The new treatment reduces the activity of the GABA α5 receptor subunit. So, it might improve mental function in people with Down Syndrome, allowing them to become more independent.
If you have Down's syndrome or know someone with Down's syndrome who is aged 18 to 30 and might be interested to hear more about this study. Please download the information flyer and the easy-read version.
Then please contact directly Dr Andre Strydom by phone or email on the details below.